EGFR and non-small cell lung carcinoma: revised their original disease specific-GPA scale to Lung-molGPA, which improved the prognostic ability over the RTOG RPA and the original disease specific-GPA by incorporating the impact of EGFR and ALK gene alterations on survival in patients with NSCLC and BM (27).